{"entity":{"id":"cediranib","kind":"drug","name":"Cediranib","aka":["AZD2171","Recentin"],"tldr":"Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.","summary":"Cediranib (AZD2171) is AstraZeneca's oral inhibitor of VEGFR-1, -2 and -3. It was tested widely, including the ICON6 trial in relapsed ovarian cancer, but never gained approval. Its clearest activity is in alveolar soft part sarcoma: a National Cancer Institute phase 2 showed responses in a third of patients, and the randomised, placebo-controlled CASPS trial (Lancet Oncology, 2019) found a greater reduction in tumour size at 24 weeks and longer progression-free survival than placebo.\n\nCediranib remains an investigational drug available in some countries through trials or special access; other VEGFR inhibitors such as sunitinib, pazopanib and anlotinib, and checkpoint inhibitors such as atezolizumab, are used in practice. The alveolar soft part sarcoma page names it among the VEGFR-directed drugs that are active in the disease.","status":"phase-2","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Cediranib","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cediranib"}],"tags":["subtype-drugs-wave"],"related":["sunitinib","pazopanib","anlotinib","atezolizumab"],"cancers":["alveolar-soft-part-sarcoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["vegf"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"AZD2171","modality":"Oral VEGFR 1-3 tyrosine kinase inhibitor","mechanism":"A potent inhibitor of all three VEGF receptors, with activity against PDGFR and KIT, that blocks tumour angiogenesis; alveolar soft part sarcoma is highly vascular and driven by the ASPSCR1-TFE3 fusion, which upregulates angiogenic genes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cediranib/","neighbours":{"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"cancer":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}